Company Filing History:
Years Active: 2016
Title: **Innovator Spotlight: Zhouning Zhang and His Contributions to Complement Activation Assays**
Introduction
Zhouning Zhang, an accomplished inventor based in Louisville, KY, has made significant strides in the field of biomedicine through his innovative work. With one patent to his name, Zhang is a vital asset in the research community and continues to advance our understanding of complement-mediated disorders.
Latest Patents
Zhouning Zhang's most notable patent, titled "Complement assays and uses thereof," offers groundbreaking methods for assessing complement activation. This invention provides techniques to evaluate the ability of various agents or conditions to modulate complement activation. Additionally, the patent covers methods for determining whether an individual has or is at increased risk of developing disorders related to complement activation, such as age-related macular degeneration (AMD). The patent also includes kits containing necessary materials for executing these methods, further bridging the gap between research and practical application.
Career Highlights
Currently, Zhouning Zhang is employed at Apellis Pharmaceuticals, Inc., where he applies his expertise toward developing therapies rooted in his research. Zhang's work is pivotal in the pursuit of innovative solutions to combat complement-mediated disorders, underlining his status as a noteworthy inventor in the pharmaceutical landscape.
Collaborations
Throughout his career, Zhouning Zhang has collaborated with esteemed colleagues such as Cedric Francois and Pascal Deschatelets. Together, they contribute to a collaborative environment that fosters innovation and the advancement of research, driving the development of new therapeutic solutions within the field.
Conclusion
Zhouning Zhang exemplifies the spirit of innovation with his significant contributions to our understanding of complement activation and its implications for health. His patent reflects not only his expertise but also a commitment to addressing critical medical challenges. As he continues his work at Apellis Pharmaceuticals, Zhang is set to inspire future advancements in biomedicine and improve outcomes for patients at risk for complement-mediated disorders.